Longeveron Achieves Milestone in Groundbreaking Stem Cell Trial for Alzheimer’s Disease – Yahoo Finance
|
Longeveron Achieves Milestone in Groundbreaking Stem Cell Trial for Alzheimer’s Disease
Yahoo Finance MIAMI, March 15, 2017 /PRNewswire/ — Longeveron, a leading stem cell research company focused on biological solutions for age-associated diseases, announced today the successful completion of enrollment in the first phase of its clinical research … |
PLoS Blogs (blog) |
Extreme makeover yeast edition: de novo synthesis of five …
PLoS Blogs (blog) What I cannot create, I do not understand. This sentence taken from Richard Feynman’s board at the time of his death essentially captures, if applied to a. New software tools streamline DNA sequence design-and-build …Phys.Org Scientists create artificial yeast in laboratories – US.Blasting.NewsBlasting News |
|
Which’ll Be First? | GenomeWeb
GenomeWeb Researchers say that the genetic engineering tool CRISPR will likely first be used in the clinic against diseases caused by single, rare mutations, CBNC reports. |
|
White paper outlines progress, challenges of immunotherapy in community setting
Healio Answer: There were several purposes. One was to review the clinical developments in immunotherapy during the past year to ‘set the stage’ for the current environment. The second was to review the work of Institute for Clinical Immuno-Oncology (ICLIO … |
OncLive |
CAR–T Therapy for DLBCL
OncLive Krishna V. Komanduri, MD: I think the next thing that’s really exciting in non-Hodgkin’s lymphoma right now, and certainly is a topic of a lot of focus at this meeting, is autologous cellular immunotherapy and CAR–T cell therapies. And I think we have … |